Clinical Trial

Study Evaluating the Efficacy of Different Mixes of HMO-2FL + Humiome® Post LB on IBS Gastrointestinal Symptoms

Study acronym: DORPHI
Completed
View on ClinicalTrials.gov →
Summary
A randomized, placebo-controlled, double-blind clinical study to evaluate the efficacy of two different mixes of HMO-2'-O-fucosyllactose (HMO-2FL) + Humiome® Post LB postbiotic (postbiotic-LB) on Gastrointestinal Symptoms in individuals with Irritable Bowel Syndrome (IBS)
Protocol Amendment History 3 changes
critical Trial completed 2026-07-23
notable Enrollment reduced: 402 -> 353 participants 2026-07-23
minor Completion moved earlier: 2026-07-30 -> 2026-06-06 2026-07-23
Trial Details
NCT Number NCT06889779
Lead Sponsor dsm-firmenich Switzerland AG
Conditions IBS (Irritable Bowel Syndrome)
Enrollment 353 participants
Start Date 2025-03-27
Primary Completion 2026-06-06 (estimated)
Study Completion 2026-06-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-22